ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: treat-to-target

Lupus Classification Criteria Expanded; Treat-to-Target Approach Gains Support

  |  

Rheumatologists at the California Rheumatology Alliance 10th Annual Medical & Scientific Meeting in San Francisco outline disease classification criteria, treat-to-target approach to lupus

Statin Guideline Eliminates Cholesterol Treat-to-Target Strategy for Managing Atherosclerotic Cardiovascular Risk

  |  

Experts question how to apply the new American College of Cardiology and American Heart Association guidelines in patients with rheumatic disease and call for further validation of the risk assessment algorithm

Insights into SLE & Lupus Nephritis From the 2025 Review Course

Jason Liebowitz, MD  |  

Review expert strategies & clinical pearls for managing SLE & lupus nephritis. Get therapeutic updates from the ACR’s 2025 Review Course.

Kidney Biopsy in Lupus Nephritis

  |  

As part of a session on lupus nephritis at ACR Convergence 2023, Simone Appenzeller, MD, PhD, shared perspectives on the importance of biopsy to inform the diagnosis, prognosis and treatment of the condition, with an emphasis on childhood disease. Prompt diagnosis and treatment of lupus nephritis is perhaps even more important for children than for…

3 AC&R Study Summaries: RA & Frailty, Hydroxychloroquine Can Protect Kidneys in Lupus Nephritis, & PT for Knee OA

  |  

Research on PT for knee OA, HCQ’s protective role in lupus nephritis & the link between RA disease activity & frailty.

Let’s Discuss Part 2: More Insights from the ACR Convergence 2025 Review Course

  |  

The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on cutaneous manifestations of rheumatic diseases, gout, macrophage activation syndrome and vasculitis.

Let’s Discuss: Insights from the ACR Convergence 2025 Review Course

  |  

The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on SLE and lupus nephritis, inflammatory brain diseases, drug management of rheumatic diseases and mimics of inflammatory myopathies.

Study: Reducing Cardiovascular Risks Helps Lupus Patients

Deborah Levenson  |  

Long-term remission & control of CVD risk factors can reduce the risk of atherosclerosis in lupus; triple APL positivity raises the risk of CVD, study finds.